Conference Reports for NATAP

Back

5th International Workshop on Hepatitis C Resistance and New Compounds 24-25 June 2010, Boston, MA USA     HCV NS5A Targeted Antivirals (BMS-790052) - (07/12/10)   Telaprevir/Peginterferon/Ribavirin - (07/01/10)   Pharmacokinetic Enhancement of HCV Protease Inhibitors with Ritonavir: More Than It Seems? - (06/30/10)   New HCV Protease: Preclinical Characteristics and Microdosing Pharmacokinetics in Healthy Volunteers Support a Low-Dose, Once-Daily Dosing Regimen of the HCV NS3/4a Protease Inhibitor ITMN-8187 - (06/28/10)   Discovery of Potent NS5A Inhibitors with Favorable Pharmacokinetics and Robust Activity in an HCV Animal Model - (06/28/10)   Chronic HCV Infection: How Does Maturation of the HCV Infected Patient Population Impact Drug Development - Gary Davis MD - (06/25/10)   Implications of host polymorphism IL28b for drug development and patient care - Mark Sulkowski MD - (06/25/10)